Keyword: Stivarga

Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.

Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.

Bayer is taking a giant colon on tour. Yes, you read that right.

A strong euro doesn't explain away Bayer's consumer health stall—or the low turnout for key cancer meds Xofigo and Stivarga.

After Lilly’s Cyramza flopped a liver cancer trial in 2014, the company designed a trial for a specific subpopulation. Now, it’s back with a win.

Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.

Bayer is working to position Stivarga as part of a liver cancer treatment regimen, But that’s not going to work in England. At least, not yet.